- Home
- CGNT vs NUVB Comparison
CGNT vs NUVB Comparison
Compare CGNT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- NUVB
- Stock Information
- Founded
- CGNT 2020
- NUVB 2018
- Country
- CGNT Israel
- NUVB United States
- Employees
- CGNT N/A
- NUVB N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- NUVB Health Care
- Exchange
- CGNT Nasdaq
- NUVB Nasdaq
- Market Cap
- CGNT 743.4M
- NUVB 679.9M
- IPO Year
- CGNT N/A
- NUVB N/A
- Fundamental
- Price
- CGNT $9.29
- NUVB $1.75
- Analyst Decision
- CGNT Hold
- NUVB Strong Buy
- Analyst Count
- CGNT 3
- NUVB 5
- Target Price
- CGNT $8.25
- NUVB $8.00
- AVG Volume (30 Days)
- CGNT 540.4K
- NUVB 2.9M
- Earning Date
- CGNT 04-02-2025
- NUVB 05-13-2025
- Dividend Yield
- CGNT N/A
- NUVB N/A
- EPS Growth
- CGNT N/A
- NUVB N/A
- EPS
- CGNT N/A
- NUVB N/A
- Revenue
- CGNT $350,632,000.00
- NUVB $7,873,000.00
- Revenue This Year
- CGNT $8.64
- NUVB $75.73
- Revenue Next Year
- CGNT $9.76
- NUVB $440.21
- P/E Ratio
- CGNT N/A
- NUVB N/A
- Revenue Growth
- CGNT 11.88
- NUVB N/A
- 52 Week Low
- CGNT $6.21
- NUVB $1.54
- 52 Week High
- CGNT $11.12
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- CGNT 56.45
- NUVB 42.56
- Support Level
- CGNT $8.45
- NUVB $1.61
- Resistance Level
- CGNT $10.32
- NUVB $1.90
- Average True Range (ATR)
- CGNT 0.54
- NUVB 0.15
- MACD
- CGNT 0.13
- NUVB 0.00
- Stochastic Oscillator
- CGNT 61.68
- NUVB 42.00
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).